The patients described in this report used medications that could cause cognitive impairment. Memantine could have antagonized these effects, through unclear mechanisms.
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Memantine may acutely improve cognition and have a mood stabilizing effect in treatment-resistant bipolar disorder Memantina pode melhorar acentuadamente a cognição e possui efeito estabilizador do humor no transtorno bipolar resistente ao tratamento Dear Editor, Bipolar patients can often show cognitive deficits, which are sometimes not associated with acute affective episodes.
1 In the most severe cases, cognitive deficits are disabling and may interfere with treatment adherence.
Cholinesterase inhibitors are used in patients with Alzheimer Disease in order to delay cognitive impairment. Donepezil was reported as a useful add-on medication in treatment-resistant bipolar patients in a case series report.
2 However, there have also been reports of mania, induced by donepezil and galantamine.
3-4
Memantine is an effective drug for the treatment of moderateto-severe cognitive impairment related to Alzheimer Disease.
5
We are reporting two cases of treatment-resistant bipolar disorder patients who showed substantial cognitive and mood symptom improvements.
Case 1 (Table 1) : a 29-year-old female fashion stylist with bipolar disorder type II and bulimia nervosa, who used to read and had been able to write short stories, was suffering from severe depression over the last 2 years, having spent most of her time in bed. She was unable to read a newspaper or to write a single letter. Lamotrigine and lithium were useful for 2 years, but they lost their efficacy. Other mood stabilizers (divalproex, carbamazepine, oxcarbazepine) were tried with no success. She did not tolerate some atypical antipsychotics, such as aripiprazol, olanzapine, quetiapine, risperidone and ziprasidone, due to severe tachycardia or reported lack of effect of these medications. In August 2005 she received memantine as an add-on treatment up to 20 mg/day. During the first week following treatment with memantine, she could go to the computer and wrote a short story, spending most of the time out of bed. After one month's treatment, she showed a moderate improvement in psychomotricity and depressive mood, along with cognitive gains.
Case 2 (Table 2) : a 32-year-old male judge (retired), with bipolar disorder type I, who had recently suffered from treatmentresistant mixed states, mostly with depressive symptoms. He reported mental incapacity, difficulty in concentrating and in performing abstract reasoning. He also reported hypomanic episodes characterized by compulsive shopping, binge eating and lack of insight. Previous unsuccessful treatments had included divalproex, oxcarbazepine, olanzapine, ziprasidone and haloperidol. The introduction of memantine up to 10 mg/day, in November 2005, promoted a rapid improvement in depressive symptoms, concentration and performance of tasks that were hitherto considered impossible, such as reading. Despite the maintenance of impulsivity, his insight into the compulsive shopping behavior and binge eating improved.
Discussion
There are similarities in the mechanism of action of memantine, an anti-glutamatergic drug, and lamotrigine, the latest drug associated with antidepressant and mood stabilizing effects in bipolar depressive patients. This mechanism of action could explain the positive effects of memantine in these treatmentresistant patients. Nós realizamos estudo transversal para determinar a taxa de prevalência de problemas de saúde mental em adolescentes que freqüentam a 6ª série do ensino fundamental de todas as escolas de Barretos-SP (amostra aleatória de 327 estudantes entre 11 e 15 anos de idade; perda amostral: 6,9%).
3-4 Os problemas de saúde mental foram definidos como anormal e/ou limítrofe, com prejuízo funcional na versão brasileira do SDQ, verificandose uma taxa de prevalência de 12,6%.
Revisão de artigos publicados no MEDLINE e LILACS revela que esta taxa está de acordo com a de outros estudos utilizando o SDQ ao redor do mundo (Tabela 1). Além disso, o SDQ tem se mostrado sensível para revelar diferenças entre classes socioeconômicas. Um estudo comparando crianças/adolescentes da região metropolitana de Campos de Jordão-SP com crianças/adolescentes moradores de favela da periferia daquele município revelou um aumento de praticamente 100% na prevalência de problemas de saúde mental no segundo grupo.
5 Resultado semelhante foi encontrado em nosso estudo quando identificamos associação entre maior taxa de problemas de saúde mental e pertencer a famílias de classes socioeconômicas mais baixas, segundo a escala ABA/ABIPEME * (p = 0,03). Portanto, a conProblemas de saúde mental em adolescentes: como identificá-los?
Mental health problems in adolescents: How to identify them?
São escassos os estudos epidemiológicos na área de saúde mental da adolescência nos países em desenvolvimento. Os altos custos desses estudos e a falta de ações preventivas em saúde pública desses países implicam em desconhecimento das necessidades das populações jovens com o subseqüente prejuízo social. O uso de instrumentos breves e confiáveis que possam viabilizar esses estudos é uma alternativa para o encaminhamento desse impasse.
O Questionário de Habilidades e Dificuldades, Strenghts and Difficultties Questionnaire (SDQ),
